PTC Therapeutics, which develops orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, filed on Thursday with the SEC to raise up to $85 million in an initial public offering. The company originally filed for an IPO in March 2006 before ultimately withdrawing its offering in 2007.
The South Plainfield, NJ-based company, which was founded in 1998 and booked $29 million in grant and collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol PTCT. The company filed confidentially on March 13, 2013. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
